Citigroup
STRO icon

Citigroup’s Sutro Biopharma STRO Stock Holding History

Citigroup’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$469K Buy
18,845
+17,802
+1,707% +$322K ﹤0.01% 3589
2025
Q4 		$12.1K Sell
1,043
-6,495
-86% -$61.6K ﹤0.01% 5003
2025
Q3 		$65.5K Buy
7,538
+4,685
+164% +$39.9K ﹤0.01% 4406
2025
Q2 		$20.4K Sell
2,853
-3,678
-56% -$30.1K ﹤0.01% 5072
2025
Q1 		$42.5K Buy
6,531
+139
+2% +$2.19K ﹤0.01% 4925
2024
Q4 		$118K Buy
6,392
+278
+5% +$8.49K ﹤0.01% 4750
2024
Q3 		$212K Buy
6,114
+4,195
+219% +$164K ﹤0.01% 4304
2024
Q2 		$56.2K Buy
1,919
+761
+66% +$30.1K ﹤0.01% 4510
2024
Q1 		$65.4K Buy
1,158
+291
+34% +$12.9K ﹤0.01% 4493
2023
Q4 		$37.2K Buy
867
+784
+945% +$24.9K ﹤0.01% 4673
2023
Q3 		$2.86K Sell
83
-1,815
-96% -$79.1K ﹤0.01% 4870
2023
Q2 		$88.3K Sell
1,898
-15,315
-89% -$762K ﹤0.01% 4304
2023
Q1 		$795K Buy
17,213
+12,844
+294% +$815K ﹤0.01% 2742
2022
Q4 		$353K Buy
4,369
+4,239
+3,261% +$295K ﹤0.01% 3394
2022
Q3 		$7K Sell
130
-264
-67% -$15.6K ﹤0.01% 5126
2022
Q2 		$21K Sell
394
-2,473
-86% -$138K ﹤0.01% 4983
2022
Q1 		$236K Sell
2,867
-4,427
-61% -$421K ﹤0.01% 3992
2021
Q4 		$1.08M Buy
7,294
+3,043
+72% +$545K ﹤0.01% 3164
2021
Q3 		$803K Sell
4,251
-9,509
-69% -$1.81M ﹤0.01% 3255
2021
Q2 		$2.56M Sell
13,760
-3,199
-19% -$626K ﹤0.01% 2471
2021
Q1 		$3.86M Buy
16,959
+11,962
+239% +$2.84M ﹤0.01% 1979
2020
Q4 		$1.08M Buy
4,997
+4,872
+3,898% +$807K ﹤0.01% 3464
2020
Q3 		$13K Sell
125
-98
-44% -$9.26K ﹤0.01% 6472
2020
Q2 		$17K Sell
223
-84
-27% -$8.06K ﹤0.01% 6752
2020
Q1 		$31K Buy
307
+89
+41% +$9.35K ﹤0.01% 6386
2019
Q4 		$24K Buy
218
+119
+120% +$12.3K ﹤0.01% 6850
2019
Q3 		$9K Sell
99
-184
-65% -$18.6K ﹤0.01% 7139
2019
Q2 		$32K Buy
283
+113
+66% +$12.5K ﹤0.01% 6822
2019
Q1 		$19K Buy
170
+1
+0.6% +$104 ﹤0.01% 6992
2018
Q4 		$16K Buy
+169
New +$20.4K ﹤0.01% 6985

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citigroup's STRO Position: Q1 2026 in Review

Citigroup increased its Sutro Biopharma (STRO) stake by 1,707% in Q1 2026, buying an estimated $322K and bringing the position to 18,845 shares worth $469K. The position accounts for ﹤0.01% of the portfolio, ranked #3589.

Citigroup first reported a position in STRO in Q4 2018 and has held it in 30 quarters since. The position peaked at $3.86M in Q1 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Citigroup held 18,845 shares of Sutro Biopharma worth $469K as of Q1 2026.
  • Citigroup bought 17,802 Sutro Biopharma shares in Q1 2026, an estimated $322K.
  • Sutro Biopharma made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3589 holding.
  • Citigroup first reported a position in Sutro Biopharma in Q4 2018 and has held it in 30 quarters since.
  • Citigroup's Sutro Biopharma position peaked at $3.86M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.